NASDAQ: FRESFresh2 Group Ltd Stock
$0.37+0.00 (+0%)
Updated Apr 15, 2024
FRES Price
$0.37
Fair Value Price
N/A
Market Cap
$3.34M
52 Week Low
$0.30
52 Week High
$9.17
P/E
-0.11x
P/B
0.26x
P/S
11.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.65M
Earnings
-$17.21M
Gross Margin
54.4%
Operating Margin
-1,055.25%
Profit Margin
-1,058.7%
Debt to Equity
0.72
Operating Cash Flow
-$8M
Beta
0.52
Next Earnings
May 16, 2024
Ex-Dividend
N/A
Next Dividend
N/A
FRES Overview
AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FRES scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FRES is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FRES is good value based on its book value relative to its share price (0.26x), compared to the US Biotechnology industry average (5.88x)
P/B vs Industry Valuation
FRES is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FRES due diligence checks available for Premium users.
Be the first to know about important FRES news, forecast changes, insider trades & much more!
FRES News
Valuation
FRES price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
14.94x
Market
41.94x
FRES price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.26x
Industry
5.88x
FRES is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FRES's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
FRES's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$24.6M
Liabilities
$9.1M
Debt to equity
0.72
FRES's short-term liabilities ($8.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FRES's short-term assets ($3.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FRES's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
FRES vs Biotech Stocks
Fresh2 Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.